We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Announces Osteoporosis Collaboration with Lilly
News

Galapagos Announces Osteoporosis Collaboration with Lilly

Galapagos Announces Osteoporosis Collaboration with Lilly
News

Galapagos Announces Osteoporosis Collaboration with Lilly

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Announces Osteoporosis Collaboration with Lilly"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that it has entered into a global collaboration agreement with Eli Lilly and Company to develop potential new medicines for the treatment of osteoporosis.

Using its proprietary SilenceSelect™ and FLeXSelect™ platforms, Galapagos has discovered and validated novel osteoporosis targets that may play a key role in bone formation.

The agreement provides Lilly access to 12 of these proprietary osteoporosis targets and drug discovery programs to discover candidate drugs. Galapagos will be responsible for the development of drug candidates potentially through to phase IIa clinical Proof of Concept.

Under the terms of the agreement, Lilly will have the exclusive option to further develop and commercialize these candidates on a worldwide basis. Galapagos will have the right to further develop and commercialize compounds for which Lilly does not exercise its option.

Galapagos will receive a €3 million upfront payment from Lilly. Contingent on achieving certain milestones, Galapagos is eligible for each target program to receive up to €88 million in discovery, development and regulatory milestones. Should a product be commercialized, Galapagos could receive up to €130 million of one-time sales milestones and up to double-digit royalties on worldwide sales of alliance products.

Advertisement